Comparative Pharmacology
Head-to-head clinical analysis: JELMYTO versus MITOSOL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: JELMYTO versus MITOSOL.
JELMYTO vs MITOSOL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
JELMYTO (mitomycin) is a mitomycin-containing gel that induces apoptosis by cross-linking DNA, inhibiting DNA synthesis, and producing reactive oxygen species, with additional local tumoricidal effects via thermal ablation of the mitomycin-containing hydrogel.
Mitomycin C is an alkylating antibiotic that inhibits DNA synthesis by forming cross-links between complementary DNA strands, thereby blocking DNA replication and transcription.
Instill 4 mg (1 vial) into the renal pelvis via ureteral catheter or nephrostomy tube, once weekly for 6 weeks, followed by monthly maintenance for up to 11 months. Administer 2 mL of sterile water for irrigation through the catheter to ensure delivery; clamp for 1 hour.
0.04 mg/kg intravenously once weekly for 4 weeks, then every 3 weeks thereafter; maximum single dose 3.5 mg.
None Documented
None Documented
Following intravesical administration, systemic absorption is negligible, so terminal half-life is not clinically relevant. Mitomycin given intravenously has a terminal half-life of 23-78 minutes (triphasic); this is not applicable for intravesical JELMYTO.
Terminal: 3-6 hours; in renal impairment, extends to 10-20 hours
JELMYTO (mitomycin) is not absorbed systemically after intravesical administration; urinary excretion is the primary route of elimination of the administered dose. Less than 1% of the dose is absorbed and undergoes hepatic metabolism and biliary/fecal excretion.
Renal: 60% unchanged; biliary/fecal: 40% as metabolites
Category C
Category C
Antineoplastic Antibiotic
Antineoplastic Antibiotic